Ly ameliorated the memory deficits of Flinders Sensitive Line rats in the object recognition job irrespective of 5-HT tone (19). Hatherall and collaboratorss (21) have lately shown that chronic vortioxetine administration decreases the excessive expression of fear memory and also the shift from active to maladaptive passive coping behavior induced by the chronic pressure remedies: chronic plus acute prolonged stress and chronic unpredictable pressure. Furthermore, MDD figures as a danger aspect for Alzheimer illness, due to the fact depressive symptoms significantly intensify the conversion of mild cognitive impairment into this dementia. Recently, Torrisi et al. (49) located that continuous remedy with either fluoxetine or vortioxetine could possibly keep away from cognitive deficits too as depressive-like phenotype inside a nontransgenic animal model of Alzheimer disease (induced by intracerebroventricular injection of amyloid- (10)) having a key contribution of transforming development factor 1. Finally, Pehrson and collaborators (20) observed that acute administration of vortioxetine reverses scopolamine (an anticholinergic agent) nduced impairments concerning socialFrontiers in Psychiatry | www.frontiersin.orgNovember 2019 | Volume ten | ArticleBennabi et al.Vortioxetine for Cognitive Enhancement in DepressionTABLE two | Randomized controls and open-label trials exploring the cognitive effects of vortioxetine in human. Authors Katona et al., 2012 (25) Design Double-blind RCT 8 weeks Double blind RCT eight weeks Population MDD three months Aged 65 yr MADRS 26 MDD three months Aged 18 and 65 yr MADRS 26 Therapy (variety of sufferers) Vortioxetine 5 mg/day (156) vs. Duloxetine 60 mg/day (151) vs. Placebo (145) Vortioxetine 10 mg/d (192) vs. Vortioxetine 20 mg/day (204) vs. Placebo (194) Cognitive assessment DSST RAVLT RAVLT DSST RAVLT TMT-A TMT-B SRT CRT Stroop test PDQ DSST TMT-A TMT-B Stroop Test Groton Maze Mastering Test Detection Activity Identification Job One-Back Task PDQ CPFQ DSST RAVLT TMT-A TMT-B Stroop test SRT CRT DSST TMT-A TMT-B Stroop test SRT CRT PDQ DSST TMT-A TMT-B Stroop test SRT CRT PDQ Principal outcomes Considerable improvement in DSST and RAVLT Vortioxetine placebo for DSST and RAVLT Duloxetine placebo only for RAVLT Vortioxetine placebo for all measures with all the exception of CRT for vortioxetine 20 mg Effect on cognitive function independent of mood improvementMcIntyre et al.GM-CSF Protein Description , 2014 (26)Mahableshwarkar et al.Bilobalide custom synthesis , 2015 (27)Double blind RCT eight weeksMDD 3 months MADRS 26 Aged 18 and 65 yrVortioxetine 10 or 20 mg/day (168) vs.PMID:32180353 Placebo (164) vs. Duloxetine 60 mg/day (176)Vortioxetine placebo for DSST, TMT-A, PDQ, attention/concentration and planning/organization subscores of PDQ Vortioxetine = duloxetine for DSST Vortioxetine = placebo for CPFQHarrison et al., 2016 (28)Double blind RCT 8 weeksMDD three months Aged 18 and 65 yr MADRSVortioxetine 10 mg/day (192) vs.Vortioxetine 20 mg/day (204) vs. Placebo (194)McIntyre et al., 2017 (29)Post hoc analysis of 5 RCT at eight weeks2,206 MDD MADRS 26 Working (1, 254) vs. nonworking patientsVortioxetine 10 mg/day vs. Vortioxetine 20 mg/day vs. PlaceboAt eight weeks, vortioxetine ten mg placebo for executive function, attention/speed of processing, memory, and DSST soon after correcting for change in depression severity At 8 weeks, vortioxetine 20 mg placebo for executive function and DSST At 1 week, vortioxetine 10 mg placebo for executive function, attention/speed of processing, DSST number of correct symbols Vortioxetine paroxetine for DSST, Stroop.
